1. Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease.
- Author
-
Plotkin JL, Day M, Peterson JD, Xie Z, Kress GJ, Rafalovich I, Kondapalli J, Gertler TS, Flajolet M, Greengard P, Stavarache M, Kaplitt MG, Rosinski J, Chan CS, and Surmeier DJ
- Subjects
- Animals, Cerebral Cortex pathology, Corpus Striatum pathology, Gene Knock-In Techniques, Huntington Disease genetics, Huntington Disease pathology, Mice, Mice, Inbred C57BL, Mice, Transgenic, Organ Culture Techniques, Receptor, trkB antagonists & inhibitors, Receptor, trkB physiology, Cerebral Cortex physiopathology, Corpus Striatum physiopathology, Disease Models, Animal, Huntington Disease physiopathology, Receptor, trkB deficiency, Signal Transduction genetics
- Abstract
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder. The debilitating choreic movements that plague HD patients have been attributed to striatal degeneration induced by the loss of cortically supplied brain-derived neurotrophic factor (BDNF). Here, we show that in mouse models of early symptomatic HD, BDNF delivery to the striatum and its activation of tyrosine-related kinase B (TrkB) receptors were normal. However, in striatal neurons responsible for movement suppression, TrkB receptors failed to properly engage postsynaptic signaling mechanisms controlling the induction of potentiation at corticostriatal synapses. Plasticity was rescued by inhibiting p75 neurotrophin receptor (p75NTR) signaling or its downstream target phosphatase-and-tensin-homolog-deleted-on-chromosome-10 (PTEN). Thus, corticostriatal synaptic dysfunction early in HD is attributable to a correctable defect in the response to BDNF, not its delivery., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF